From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
ENMD-2076 is a multi-targeted kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively.
Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM) .
ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively.
FLT4 Human Pre-designed siRNA Set A contains three designed siRNAs for FLT4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Flt4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Flt4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Flt4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Flt4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Vatalanib (PTK787) succinate is a potent and orally active VEGFR inhibitor with IC50s of 37 nM, 77 nM, 270 nM, 660 nM, 730 nM, 1400 nM, and 580 nM for KDR, Flt-1, Flk, Flt-4, c-Kit, c-Fms, and PDGFR-β, respectively .
Vandetanib hydrochloride (D6474 hydrochloride) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib hydrochloride also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM) .
Vandetanib trifluoroacetate (D6474 trifluoroacetate) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib trifluoroacetate also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM) .
Gandotinib (LY2784544) is a potent JAK2 inhibitor with IC50 of 3 nM. Gandotinib (LY2784544) also inhibits FLT3, FLT4, FGFR2, TYK2, and TRKB with IC50 of 4, 25, 32, 44, and 95 nM.
Cediranib maleate (AZD-2171 maleate) is a highly potent, orally available VEGFR inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.
Cediranib (AZD2171) is a highly potent, orally available VEGFR tyrosine kinase inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.
Vandetanib (Standard) is the analytical standard of Vandetanib. This product is intended for research and analytical applications. Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM) .
Vandetanib-d4 is the deuterium labeled Vandetanib. Vandetanib (ZD6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1][2].
Vandetanib-d6 is the deuterium labeled Vandetanib. Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1].
MAZ51 is a selective inhibitor of VEGFR-3 (Flt-4) tyrosine kinase. MAZ51 inhibits VEGF-C-induced activation of VEGFR-3 without blocking VEGF-C-mediated stimulation of VEGFR2. MAZ51 had no effect on ligand-induced autophosphorylation of EGFR, IGF-1R and PDGFRβ. MAZ51 blocks proliferation and induces apoptosis in a wide variety of tumor cells. Antitumor activity .
Vandetanib-13C6 is a deuterated labeled Vandetanib . Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM) .
Tesevatinib (XL-647; EXEL-7647; KD-019) is an orally available, multi-target tyrosine kinase inhibitor; inhibits EGFR, ErbB2, KDR, Flt4 and EphB4 kinase with IC50s of 0.3, 16, 1.5, 8.7, and 1.4 nM.
Cediranib (Standard) is the analytical standard of Cediranib. This product is intended for research and analytical applications. Cediranib (AZD2171) is a highly potent, orally available VEGFR tyrosine kinase inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.
Multi-kinase inhibitor 4 (compound 14) is an orally active inhibitor of FLT1, KDR, FLT3, FLT4, PDGFRα, PDGFRβ, with IC50s of 1.97 nM, 1.04 nM, 0.33 nM, 1.44 nM, 0.18 nM, 0.89 nM. Multi-kinase inhibitor 4 plays an important role in cancer research .
TNIK-IN-3 is a potent, selective and orally active inhibitor of Traf2- and Nck-interacting protein kinase (TNIK), with an IC50 of 0.026 μM. TNIK-IN-3 could also inhibit Flt4 (IC50=0.030 μM), Flt1 (IC50=0.191 μM) and DRAK1 (IC50=0.411 μM). TNIK-IN-3 can be used for the research of colorectal cancer .
Antiproliferative agent-34 (Compound A14) is a multi-target kinase inhibitor, with an IC50 of 177 nM and 1567 nM for EGFR L858R/T790M and EGFR WT. Antiproliferative agent-34 also inhibits JAK2, ROS1, FLT3, FLT4, PDGFRα with IC50 of 30.93, 106.90, 108.00, 226.60, 42.53 nM. Antiproliferative agent-34 inhibits H1975 and HCC827 cells proliferation with IC50 values below 40 nM under normoxic condition, and the anti-proliferation potency achieves 4–6-fold improvement (IC50 values < 10 nM) under hypoxic condition .
VEGFR-3/FLT4 proteins are tyrosine protein kinase receptors for VEGFC and VEGFD and are critical in adult lymphangiogenesis and embryonic vascular development. It promotes endothelial cell function, angiogenesis, and forms a positive feedback loop that increases VEGFC production. VEGFR-3/FLT4 Protein, Mouse (HEK293, His) is the recombinant mouse-derived VEGFR-3/FLT4 protein, expressed by HEK293 , with C-His labeled tag. The total length of VEGFR-3/FLT4 Protein, Mouse (HEK293, His) is 751 a.a., with molecular weight of 95-105 kDa.
VEGFR-3/FLT4 proteins are tyrosine protein kinase receptors for VEGFC and VEGFD and are critical in adult lymphangiogenesis and embryonic vascular development. It promotes endothelial cell function, angiogenesis, and forms a positive feedback loop that increases VEGFC production. VEGFR-3/FLT4 Protein, Mouse (HEK293, hFc) is the recombinant mouse-derived VEGFR-3/FLT4 protein, expressed by HEK293 , with C-hFc labeled tag. The total length of VEGFR-3/FLT4 Protein, Mouse (HEK293, hFc) is 751 a.a., with molecular weight of 115-160 kDa.
VEGFR-2 protein is an important tyrosine protein kinase receptor that serves as a cell surface receptor for VEGFA, VEGFC and VEGFD to regulate angiogenesis, blood vessel development and embryonic hematopoiesis. It enhances endothelial cell proliferation, survival, migration and differentiation. VEGFR-3/FLT4 Protein, Human (HEK293, His) is the recombinant human-derived VEGFR-3/FLT4 protein, expressed by HEK293 , with C-His labeled tag.
The VEGF-CC protein is a potent growth factor in angiogenesis and endothelial cell growth, stimulating cell proliferation and migration while affecting vascular permeability. It plays a critical role in embryonic vein and lymphangiogenesis and maintains adult differentiated lymphatic endothelium. VEGF-CC Protein, Human (196a.a, HEK293, His) is the recombinant human-derived VEGF-CC protein, expressed by HEK293 , with C-6*His labeled tag. The total length of VEGF-CC Protein, Human (196a.a, HEK293, His) is 196 a.a., with molecular weight of 25-30 kDa.
VEGF-C protein is an important member of the PDGF/VEGF growth factor family and plays a role in important cell signaling pathways. As part of this family, VEGF-C may share features with related proteins that promote cell growth, angiogenesis, and lymphangiogenesis. VEGF-C Protein, Human (HEK293, His-Avi) is the recombinant human-derived VEGF-C protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of VEGF-C Protein, Human (HEK293, His-Avi) is 125 a.a., with homodimer molecular weight of ~23-30 kDa.
VEGF-C protein is an important member of the PDGF/VEGF growth factor family and plays a role in important cell signaling pathways. As part of this family, VEGF-C may share features with related proteins that promote cell growth, angiogenesis, and lymphangiogenesis. VEGF-C Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived VEGF-C protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of VEGF-C Protein, Human (Biotinylated, HEK293, His-Avi) is 125 a.a., with homodimer molecular weight of ~23-30 kDa.
VEGF-CC protein stimulates cell proliferation, migration, and vascular permeability, which are critical for angiogenesis and endothelial cell dynamics. It plays a crucial role in the development of the venous and lymphatic vasculature during embryogenesis and in the maintenance of adult lymphatic endothelium. VEGF-CC Protein, Mouse/Rat (HEK293, His) is the recombinant mouse, rat-derived VEGF-CC protein, expressed by HEK293 , with C-6*His labeled tag. The total length of VEGF-CC Protein, Mouse/Rat (HEK293, His) is 116 a.a., with molecular weight of 14-23 kDa.
VEGFR-2 protein is an important tyrosine protein kinase receptor that serves as a cell surface receptor for VEGFA, VEGFC and VEGFD to regulate angiogenesis, blood vessel development and embryonic hematopoiesis. It enhances endothelial cell proliferation, survival, migration and differentiation. VEGFR-3/FLT4 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived VEGFR-3/FLT4 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
VEGFR-2 protein is an important tyrosine protein kinase receptor that serves as a cell surface receptor for VEGFA, VEGFC and VEGFD to regulate angiogenesis, blood vessel development and embryonic hematopoiesis. It enhances endothelial cell proliferation, survival, migration and differentiation. VEGFR-3/FLT4 Protein, Human (HEK293, hFc) is the recombinant human-derived VEGFR-3/FLT4 protein, expressed by HEK293 , with C-hFc labeled tag.
VEGFR-2 protein is an important tyrosine protein kinase receptor that serves as a cell surface receptor for VEGFA, VEGFC and VEGFD to regulate angiogenesis, blood vessel development and embryonic hematopoiesis. It enhances endothelial cell proliferation, survival, migration and differentiation. VEGFR-3/FLT4 Protein, Human (HEK293, His-Avi) is the recombinant human-derived VEGFR-3/FLT4 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
VEGF-CC protein stimulates cell proliferation, migration, and vascular permeability, which are critical for angiogenesis and endothelial cell dynamics. It plays a crucial role in the development of the venous and lymphatic vasculature during embryogenesis and in the maintenance of adult lymphatic endothelium. VEGF-CC Protein, Mouse/Rat (HEK293, Fc) is the recombinant rat, mouse-derived VEGF-CC protein, expressed by HEK293 , with N-hFc labeled tag. The total length of VEGF-CC Protein, Mouse/Rat (HEK293, Fc) is 116 a.a., with molecular weight of ~44 & 34 kDa, respectively.
VEGF-C Protein, Human (116a.a, HEK293) functions in lymphangiogenesis, where it acts on lymphatic endothelial cells (LECs) primarily via its receptor VEGFR-3 promoting survival, growth and migration.
The VEGF-CC protein is a potent growth factor in angiogenesis and endothelial cell growth, stimulating cell proliferation and migration while affecting vascular permeability. It plays a critical role in embryonic vein and lymphangiogenesis and maintains adult differentiated lymphatic endothelium. VEGF-CC Protein, Human (125a.a, HEK293, His) is the recombinant human-derived VEGF-CC protein, expressed by HEK293 , with C-His labeled tag. The total length of VEGF-CC Protein, Human (125a.a, HEK293, His) is 125 a.a., with molecular weight of ~22.5 kDa.
The VEGF-CC protein is a potent growth factor in angiogenesis and endothelial cell growth, stimulating cell proliferation and migration while affecting vascular permeability. It plays a critical role in embryonic vein and lymphangiogenesis and maintains adult differentiated lymphatic endothelium. VEGF-C Protein, Human (116a.a, HEK293, His) is the recombinant human-derived VEGF-C protein, expressed by HEK293 , with C-6*His labeled tag. The total length of VEGF-C Protein, Human (116a.a, HEK293, His) is 116 a.a., with molecular weight of ~19.42 kDa.
Vandetanib-d4 is the deuterium labeled Vandetanib. Vandetanib (ZD6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1][2].
Vandetanib-d6 is the deuterium labeled Vandetanib. Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM)[1].
Vandetanib-13C6 is a deuterated labeled Vandetanib . Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM) .
FLT4 Human Pre-designed siRNA Set A contains three designed siRNAs for FLT4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Flt4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Flt4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Flt4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Flt4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Inquiry Online
Your information is safe with us. * Required Fields.
